University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Published

April 29, 2022

University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...